New imaging agent could predict CAR-T success in lymphoma patients
NCT ID NCT06522932
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing a new radioactive tracer called 64Cu-GRIP B, which is used in PET scans to detect immune cell activity. The goal is to see if this scan can predict which patients with relapsed non-Hodgkin lymphoma will have a lasting response to CAR-T cell therapy. About 32 adults will receive the tracer before and after CAR-T treatment, and some will also have optional tumor biopsies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
64Cu-GRIP B (a radioactive tracer for PET scans)
What this could lead to
If successful, this imaging method could help doctors quickly identify which lymphoma patients are likely to benefit from CAR-T therapy, avoiding ineffective treatments.
What could go wrong
This is a very early, small study (32 people) focused on imaging, not treatment. The tracer may not reliably predict responses, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.